期刊簡介 | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | LANCET ONCOLOGY LetPub Score 9.8
50 ratings
Rate
Reputation 10.0 Influence 9.7 Speed 9.3 | ||||||||||||||||
期刊簡稱 | LANCET ONCOL | ||||||||||||||||
ISSN | 1470-2045 | ||||||||||||||||
E-ISSN | 1474-5488 | ||||||||||||||||
h-index | 274 | ||||||||||||||||
CiteScore |
| ||||||||||||||||
自引率 (2023-2024) | 1.20%自引率趨勢 | ||||||||||||||||
掲載範囲 |
| ||||||||||||||||
官方網站 | http://www.thelancet.com/journals/lanonc/issue/current | ||||||||||||||||
在線稿件提交 | https://www.editorialmanager.com/THELANCETONCOLOGY | ||||||||||||||||
開放訪問 | No | ||||||||||||||||
出版商 | Lancet Publishing Group | ||||||||||||||||
主題領域 | 医学 | ||||||||||||||||
出版國/地區 | UNITED STATES | ||||||||||||||||
發行頻率 | 月刊 | ||||||||||||||||
創刊年 | 2000 | ||||||||||||||||
每年文章數 | 126每年文章數趨勢 | ||||||||||||||||
黃金OA百分比 | 18.31% | ||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q1
| ||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1470-2045%5BISSN%5D | ||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Ordinary, 3-8 Week(s) | ||||||||||||||||
競爭力 * | 來自作者的數據: Extremely difficult | ||||||||||||||||
參考鏈接 |
| ||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
首頁 上一頁 1 2 下一頁 末頁 (頁 | |
[LANCET ONCOLOGY] 的評論 | 撰寫評論 |
作者: Adelaide Lawson 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2024-07-16 08:42:36 評論於 The basic article is being received.(0) 讚! | Adelaide Lawson |
作者: 是志丹吖 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2024-06-19 20:32:31 評論於 Review speed: 3.0 | Submission hit rate: 5.0 Emphasis on research directions: tumors; tumor immunotherapy; solid tumor experience sharing: The impact factor for the year 2023 is 41.6, which is still good overall and still in a leading position in the field of oncology. CA-A CANCER JOURNAL FOR CLINICIANS, 503.1, dominates with one article, without considering Nature Reviews Clinical Oncology 81.3, mainly publishes reviews. ANNALS OF ONCOLOGY, 56.7, mainly reviews. CANCER CELL 48.8, mainly focuses on translational medicine, and starting from the past two years, also publishes some clinical trial articles. JOURNAL OF CLINICAL ONCOLOGY, 42.1, is similar to LANCET ONCOLOGY, ranking equally. Moving down, Cancer Discovery, 29.7, also publishes articles on basic research and translational medicine, which are further from clinical practice. Journal of Hematology & Oncology 29.5 is a comprehensive journal for hematologic tumors and solid tumors. Molecular Cancer 27.7 is also related to tumor translational medicine.(0) 讚! | 是志丹吖 |
作者: 北国迎荷 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2024-06-08 09:31:42 評論於 Please translate the following passage into English: 8(0) 讚! | 北国迎荷 |
作者: 混元新曦 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-07-18 22:18:18 評論於 Haha, the road of scientific research is long in life(0) 讚! | 混元新曦 |
作者: 混元新曦 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-07-18 09:23:18 評論於 The Lancet journal is fine as long as the article is good. If the journal invites submissions, it can still be accepted(0) 讚! | 混元新曦 |
作者: 是志丹吖 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-06-28 22:03:56 評論於 Impact factor of 51.1, top journal(0) 讚! | 是志丹吖 |
作者: 擒龙小谷 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-05-26 15:17:57 評論於 Submitting articles every day, worrying every day(0) 讚! | 擒龙小谷 |
作者: 坠星倩影 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-05-03 13:36:31 評論於 It's best(0) 讚! | 坠星倩影 |
作者: 两仪景胜 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-11-06 18:28:21 評論於 Looking forward, multicenter is the mainstream, everything else is outdated(0) 讚! | 两仪景胜 |
作者: 一二三四我是小雨点点 領域: 医学 審稿時間: 1.0 month(s) 結果: 拒稿 撰寫評論 |
2022-03-30 22:03:13 評論於 The editor was very nice, although my submission was ultimately rejected. However, the rejection letter was sincere and included substantive feedback specific to my article. In the end, they recommended another journal and suggested transferring my submission there.(0) 讚! | 一二三四我是小雨点点 |
作者: 法慧和同 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-02-10 19:47:52 評論於 Unless it is a super large sample(0) 讚! | 法慧和同 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 21:19:53 評論於 2 weeks to 3 months(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 14:07:37 評論於 The review process may be taking longer than expected, and it has not been completed yet(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 深渊兴业 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-28 17:43:23 評論於 Why haven't I heard back after a month of applying?(0) 讚! | 深渊兴业 |
作者: 北国博达 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-27 23:10:31 評論於 How long does it usually take for a journal to review a manuscript?(0) 讚! | 北国博达 |
作者: 法慧和同 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-09-11 21:09:18 評論於 Of course(0) 讚! | 法慧和同 |
作者: 法慧和同 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-09-11 16:32:14 評論於 It is best to add some conversion research(0) 讚! | 法慧和同 |
作者: 运骏姑娘 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-09-09 09:34:46 評論於 Can a purely clinical research RCT be conducted?(0) 讚! | 运骏姑娘 |
作者: 采南小姐姐 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-09-05 16:26:36 評論於 Very visionary(0) 讚! | 采南小姐姐 |
作者: Q-q 領域: 医学 審稿時間: 4.0 month(s) 結果: 待定&不明 撰寫評論 |
2020-06-26 22:07:04 評論於 It has been more than 4 months since I submitted the manuscript, and there has been no news. Unexpectedly, I was told that no reviewers were found. Is it because of the serious pandemic in Europe and America? SAD! (41) 讚! | Q-q |
作者: 深渊妙芙 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2020-03-13 23:01:56 評論於 How many people can share one?(0) 讚! | 深渊妙芙 |
作者: 太山羽沫 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2019-11-15 20:23:54 評論於 Are you accepting retrospective cohort studies?(0) 讚! | 太山羽沫 |
作者: 中原兴思 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2019-06-21 19:19:05 評論於 We only accept transformational research articles, not purely foundational ones(0) 讚! | 中原兴思 |
作者: 中原兴思 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2019-06-21 09:11:43 評論於 Zhou often publishes this periodical. 153****5167 (no pseudonym) Published on 2017-02-02 Research area: tumors; cancer; SCI (2015): 26.509 SCI (2014): 24.69 is Zhou Caicun(0) 讚! | 中原兴思 |
作者: 寂灭巧易 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2019-01-20 09:34:28 評論於 Classmate, does this magazine submission require an analysis? Especially the author's information, font size and format requirements, I have found them all(0) 讚! | 寂灭巧易 |
首頁 上一頁 1 2 下一頁 末頁 (頁 |
Contact us